ArticleLiver cancer2026
Outcomes by Comorbidities with Tremelimumab and Durvalumab in the Randomized, Controlled Phase 3 HIMALAYA Study in Unresectable Hepatocellular Carcinoma.
Article in Liver cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03298451 (A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: People with hepatocellular carcinoma (HCC) often have underlying comorbidities, which may impact prognosis and lead to safety challenges following treatment. This exploratory, post hoc analysis of the phase 3 HIMALAYA study (NCT03298451) assessed outcomes in participants with unresectable HCC and cardiovascular or metabolic comorbidities at baseline. Methods: Participants with unresectable HCC were randomized to STRIDE (Single Tremelimumab Regular Interval Durvalumab), durvalumab monotherapy, or sorafenib. Comorbidities were based on medical history assessed at baseline and qualified using preferred terms from cardiovascular or metabolic Standardised Medical Dictionary for Regulatory Activities Queries. Overall survival (OS) rates were evaluated in participants with or without cardiovascular or metabolic comorbidities within and by treatment group. The proportion of long-term survivors (alive ≥36 months post-randomization) and safety were assessed in participants with cardiovascular or metabolic comorbidities. Data cutoffs: August 27, 2021 (primary analysis); January 23, 2023 (4-year updated analysis, OS, and serious treatment-related adverse events). Results: Hypertension and type 2 diabetes mellitus were the most common cardiovascular and metabolic comorbidities, respectively. The 48-month OS rates with STRIDE were 28.0% and 21.7% in participants with and without cardiovascular comorbidities and 20.4% and 28.5% in those with and without metabolic comorbidities, respectively. In total, 28.2% of participants with cardiovascular comorbidities and 22.6% of participants with metabolic comorbidities experienced long-term survival with STRIDE. Safety in participants with cardiovascular or metabolic comorbidities was generally consistent with all participants in the safety analysis set; no new safety signals were observed. Conclusions: OS benefits with STRIDE were similar in participants with vs. without cardiovascular or metabolic comorbidities, with manageable safety in participants with comorbidities. These results support the durable benefits of STRIDE in a broad population reflective of unresectable HCC globally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.